AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Development of AECOPD Identification Tool (DETECT Study)

Completed

Conditions: Acute Exacerbations of COPD

First Posted Date: 2018-06-14

Last Posted Date: 2022-04-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 300

Registration Number: NCT03556475

Locations: 🇨🇳
Research Site, Xinxiang, China

A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

Phase 3

Completed

Conditions: Reflux Esophagitis
Gastric Ulcer
Duodenal Ulcer

Interventions: Drug: D961H capsule 10mg
Drug: D961H sachet 10mg

First Posted Date: 2018-06-12

Last Posted Date: 2023-04-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 51

Registration Number: NCT03553563

Locations: 🇯🇵
Research Site, Yokohama-shi, Japan

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours.

Phase 1

Completed

Conditions: Malignant Solid Tumor

Interventions: Drug: Olaparib Treatment A
Drug: Olaparib Treatment B
Drug: Olaparib Treatment C
Drug: Olaparib Treatment D

First Posted Date: 2018-06-12

Last Posted Date: 2020-10-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT03553108

Locations: 🇧🇪
Research Site, Wilrijk, Belgium

iCaReMe Global Registry

Recruiting

Conditions: Heart Failure
Hypertension
Type 2 Diabetes
Chronic Kidney Disease

First Posted Date: 2018-06-08

Last Posted Date: 2025-06-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 35000

Registration Number: NCT03549754

Locations: 🇦🇪
Research Site, Sharjah, United Arab Emirates

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3

Active, not recruiting

Conditions: Relapsed Ovarian Cancer
Platinum Sensitive
Following Complete or Partial Response to Platinum Based Chemotherapy

Interventions: Drug: Olaparib 300mg tablets

First Posted Date: 2018-05-23

Last Posted Date: 2024-08-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 229

Registration Number: NCT03534453

Locations: 🇲🇾
Research Site, Putrajaya, Malaysia

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

Phase 2

Terminated

Conditions: Heart Failure

Interventions: Drug: Sodium Zirconium Cyclosilicate
Drug: Placebo

First Posted Date: 2018-05-22

Last Posted Date: 2021-06-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 182

Registration Number: NCT03532009

Locations: 🇸🇰
Research Site, Svidnik, Slovakia

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.

Phase 3

Completed

Conditions: Hyperkalemia

Interventions: Drug: Placebo
Drug: Sodium Zirconium Cyclosilicate 10g
Drug: Sodium Zirconium Cyclosilicate 5g

First Posted Date: 2018-05-18

Last Posted Date: 2025-05-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 270

Registration Number: NCT03528681

Locations: 🇮🇳
Research Site, Vijayawada, India

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Phase 3

Active, not recruiting

Conditions: Non-muscle-invasive Bladder Cancer

Interventions: Biological: Durvalumab (MEDI4736)
Biological: Bacillus Calmette-Guerin (BCG)

First Posted Date: 2018-05-18

Last Posted Date: 2025-05-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 1018

Registration Number: NCT03528694

Locations: 🇬🇧
Research Site, Taunton, United Kingdom

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

Phase 3

Active, not recruiting

Conditions: Non Small Cell Lung Cancer (Stage III)

Interventions: Drug: Osimertinib 80mg/40mg
Drug: Placebo Osimertinib 80mg/40mg

First Posted Date: 2018-05-11

Last Posted Date: 2025-04-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 216

Registration Number: NCT03521154

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Other: Placebo
Drug: Cisplatin/ Etoposide
Drug: Carboplatin/ Paclitaxel
Drug: Pemetrexed/ Cisplatin
Drug: Pemetrexed/ Carboplatin
Radiation: Radiation

First Posted Date: 2018-05-09

Last Posted Date: 2025-04-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 328

Registration Number: NCT03519971

Locations: 🇻🇳
Research Site, Ho Chi Minh, Vietnam

Home Terms & Conditions Privacy Policy